anatomical_structure

BBB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about BBB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

146Connections

30Hypotheses

13Analyses

50Outgoing

34Incoming

8Experiments

20Debates

Summary

BBB is an entity related to neurodegeneration research. Key relationships include: co discussed, associated with, regulates. Associated with ALS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE. Connected to 70 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

Wiki Pages (8)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    BBB["Blood-Brain Barrier"] -->|"Components"| EC["Endothelial Cells"]
    BBB -->|"Components"| TJ["Tight Junctions"]
    BBB -->|"Components"| Pericytes["Pericytes"]
    BBB -->|"Components"| Astrocytes["Astrocytic End-feet"]
    EC -->|"Express"| Transporters["ABC Transporters"]
    TJ -->|"Seal"| Gaps["Paracellular Gaps"]
    BBB -->|"Regulates"| Influx["Nutrient Influx"]
    BBB -->|"Regulates"| Efflux["Waste Efflux"]
    Aging -.Causes.-> Breakdown["BBB Breakdown"]
    Breakdown -.Allows.-> Entry["Toxin Entry"]
    Entry -.Contributes to.-> ND["Neurodegeneration"]

Outgoing (112)

Target	Relation	Type	Str
MMP2	co_discussed	entity	0.50
MMP9	co_discussed	entity	0.50
PERICYTE	co_discussed	entity	0.50
PERICYTES	co_discussed	entity	0.50
HIPPOCAMPUS	co_discussed	entity	0.50
STING	co_discussed	entity	0.50
TAU	co_discussed	entity	0.50
MICROGLIA	co_discussed	entity	0.50
NEUROINFLAMMATION	co_discussed	entity	0.50
NEURONS	co_discussed	cell_type	0.50
P2RY12	co_discussed	entity	0.50
LRP1	co_discussed	entity	0.50
T CELL	co_discussed	entity	0.50
SLEEP	co_discussed	entity	0.50
MAPT	co_discussed	entity	0.50
MTOR	co_discussed	entity	0.50
COMPLEMENT	co_discussed	entity	0.50
ERK	co_discussed	entity	0.50
MACROPHAGE	co_discussed	entity	0.50
MACROPHAGES	co_discussed	entity	0.50
MONOCYTE	co_discussed	entity	0.50
EPIGENETIC	co_discussed	entity	0.50
INFLAMMASOME	co_discussed	entity	0.50
GLYMPHATIC	co_discussed	entity	0.50
DEMENTIA	co_discussed	entity	0.50
GLIOBLASTOMA	co_discussed	entity	0.50
TBI	co_discussed	entity	0.50
OCLN	co_discussed	entity	0.50
FUS	co_discussed	entity	0.50
STRIATUM	co_discussed	entity	0.50
THALAMUS	co_discussed	entity	0.50
BDNF	co_discussed	entity	0.50
SYNAPTIC PLASTICITY	co_discussed	entity	0.50
TREM2	co_discussed	entity	0.50
HIF1A	co_discussed	entity	0.50
WHITE MATTER	co_discussed	entity	0.50
PARP1	co_discussed	entity	0.50
BLOOD-BRAIN BARRIER	co_discussed	entity	0.50
ENDOTHELIAL	co_discussed	entity	0.50
STROKE	co_discussed	entity	0.50
CLDN5	co_discussed	entity	0.50
BECN1	co_discussed	entity	0.50
NEURODEGENERATION	co_discussed	entity	0.50
PARKINSON	co_discussed	entity	0.50
PARKINSON'S	co_discussed	entity	0.50
MS	co_discussed	entity	0.50
MULTIPLE SCLEROSIS	co_discussed	entity	0.50
OLIGODENDROCYTE	co_discussed	entity	0.50
NMDA	co_discussed	entity	0.50
CEREBELLUM	co_discussed	entity	0.50

Incoming (34)

Source	Relation	Type	Str
35361905	is vital for maintaining	paper	0.90
35361905	prevents	paper	0.90
35361905	breaks down with	paper	0.90
CLDN5	regulates	gene	0.90
autophagy	alleviates	process	0.90
25757756	degrades	paper	0.90
CLDNs	disrupts	gene	0.80
CLAUDIN5	regulates	protein	0.72
AUTOPHAGY	regulates	pathway	0.72
HYPOXIA	causes	phenotype	0.72
Peripheral monocytes	traffics_across	cell_type	0.70
ENDOTHELIAL CELLS	protects_against	cell_type	0.65
STROKE	causes	disease	0.64
MONOCYTES	interacts_with	cell_type	0.64
35361905	is connected with	paper	0.60
ALZHEIMER	co_discussed	entity	0.50
ALZHEIMER'S	co_discussed	entity	0.50
APOE	co_discussed	entity	0.50
ASTROCYTE	co_discussed	entity	0.50
ASTROCYTES	co_discussed	entity	0.50
ATG5	co_discussed	entity	0.50
APOPTOSIS	co_discussed	entity	0.50
ALS	co_discussed	entity	0.50
AQP4	co_discussed	entity	0.50
ANGIOGENESIS	co_discussed	entity	0.50
AKT	co_discussed	entity	0.50
AXON	co_discussed	entity	0.50
AMPK	co_discussed	entity	0.50
B CELL	co_discussed	entity	0.50
BACE1	co_discussed	entity	0.50
ABCA1	co_discussed	entity	0.50
APP	co_discussed	entity	0.50
AUTOPHAGY	co_discussed	entity	0.50
ABETA	co_discussed	entity	0.50

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Plasma NfL Elevation Secondary to BBB-Associated Transport D	0.940	-	What blood-brain barrier permeability ch
VHH-Fc Fusion Constructs with Separate BBB-Targeting Moiety	0.750	neurodegeneration	Blood-brain barrier antibody transport m
Matrix Metalloproteinase-9 and TIMP-1 Ratio in Peripheral Bl	0.735	-	What blood-brain barrier permeability ch
Synthetic Biology BBB Endothelial Cell Reprogramming	0.727	neurodegeneration	Blood-brain barrier transport mechanisms
Calcium-Dependent S100B Release from Astrocyte End-Feet as a	0.725	-	What blood-brain barrier permeability ch

APOE4-driven pericyte injury/senescence is an upstream drive	0.720	neurodegeneration	Does pericyte senescence drive BBB break
Gut-BBB Axis: Tributyrin/Butyrate HDAC Inhibition Epigenetic	0.712	-	Blood-brain barrier permeability changes
Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellu	0.705	-	What blood-brain barrier permeability ch
Endothelial NRF2 Activation as a Master Switch for Post-CA B	0.689	neurodegeneration	View
Soluble LRP1 (sLRP1) Ectodomain Shedding as a Blood-Based In	0.680	-	What blood-brain barrier permeability ch
CSF/Serum NfL Ratio Discriminates Active Transcytosis from P	0.665	-	What blood-brain barrier permeability ch
GFAP-Bearing Circulating Extracellular Vesicles Originating	0.665	-	What blood-brain barrier permeability ch
BBB Integrity Loss Defines Absolute Therapeutic Window Closu	0.660	neurodegeneration	What is the optimal therapeutic window f
Time-Dependent BBB Repair Strategy	0.656	-	Blood-brain barrier tight junction disru
S100B as Active Pathogenic BBB-Disrupting Signal via RAGE/NF	0.647	-	Blood-brain barrier permeability changes
Endothelial miR-181c-5p Upregulation Drives Claudin-5 Repres	0.645	-	What blood-brain barrier permeability ch
Circulating Endothelial Microvesicles Expressing Degraded Cl	0.640	-	What blood-brain barrier permeability ch
Matrix Metalloproteinase-9 and TIMP-1 Ratio in Peripheral Bl	0.640	-	What blood-brain barrier permeability ch
Pericyte senescence is sufficient to weaken the BBB even wit	0.630	neurodegeneration	Does pericyte senescence drive BBB break
Integrated Blood Panel of sPDGFRβ, sTM, and Circulating micr	0.625	-	What blood-brain barrier permeability ch
GFAP Perivascular Redistribution (End-Feet Retraction) as Tr	0.594	-	Blood-brain barrier permeability changes
P2RY12-driven autophagy impairment in cerebral VSMCs mediate	0.585	neurodegeneration	How does P2RY12-mediated VSMC dysfunctio
Vascular and Perivascular Cell Type Vulnerability: BBB Integ	0.566	neurodegeneration	Cell type vulnerability debate in Alzhei
BBB leak induces secondary pericyte senescence through TGF-b	0.560	neurodegeneration	Does pericyte senescence drive BBB break
Fusing IGFBPL1 to IGF-1 for Receptor-Mediated BBB Transcytos	0.552	drug delivery	Can IGFBPL1 therapeutics effectively cro
Systemic IL-6–STAT3–Hepatic C3 Axis and BBB-Mediated Complem	0.540	neuroinflammation	How does sevoflurane-induced NF-κB activ
Piezoelectric Nanochannel BBB Disruption	0.519	neurodegeneration	Blood-brain barrier transport mechanisms
CSF p-tau217 Normalization Requires Intact Synaptic Function	0.515	neurodegeneration	-
SIRT1-Mediated Epigenetic Restoration of MFSD2A Expression R	0.500	neuropharmacology	What determines blood-brain barrier pene
Soluble LRP1 Fragments Serve as Blood-Based Indicators of Im	0.485	-	What blood-brain barrier permeability ch

Mentioning Analyses (13)

Scientific analyses that reference this entity

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

neurodegeneration | 2026-04-26 | 5 hypotheses Top: 0.712

Can ferroptosis inhibitors prevent BBB disruption and edema formation after card

neurodegeneration | 2026-04-25 | 7 hypotheses Top: 0.760

Blood-brain barrier tight junction disruption by neuroinflammatory cytokines

neurodegeneration | 2026-04-16 | 7 hypotheses Top: 0.919

How do synthetic EVs achieve brain-specific targeting while avoiding reticuloend

drug delivery | 2026-04-15 | 0 hypotheses

How does engineered C. butyricum cross the blood-brain barrier to directly bind

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.699

Experiments (8)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
s:** - Compare uptake with/without magnetic particles using tight junc	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$120,000
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
AAV Serotype Comparison for LRRK2 Knockdown in PD	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
Blood-Based Biomarker Panel for Early AD Detection	clinical	Alzheimer's Disease	0.400	0.50	cell_line	proposed	$220,000
Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur	validation	Neurodegeneration	0.400	0.50	cell_line	proposed	$130,000
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
Vascular Contribution to Alzheimer's Disease — Beyond Amyloid	validation	Alzheimer's Disease	0.400	0.50	human	proposed	$2,280,000

Related Papers (11)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic bas [PMID:36577758]	Gharbi Severine Isabelle; Pelletier Laur	NPJ breast cancer	2022
The biology of beauty sleep. [PMID:35256810]	Jordan A Anderson; Jenny Tung	Nature ecology & evolution	2022
Cathepsin S is a novel target for age-related dry eye. [PMID:34910926]	["Yu Z", "Li J", "Govindarajan G", "Hamm	Experimental eye research	2022
Intrinsic functional neuron-type selectivity of transcranial focused ultrasound [PMID:33947867]	["Yu K", "Niu X", "Krook-Magnuson E", "H	Nature communications	2021
Warning wristbands for patients with intra-ocular gas [PMID:31745326]	Naderi Khayam; Masoero Pietro; Karthikey	Eye	2020
NK cells for cancer immunotherapy. [PMID:31907401]	["Shimasaki N", "Jain A", "Campana D"]	Nature reviews. Drug discovery	2020
Potent and specific MTH1 inhibitors targeting gastric cancer. [PMID:31164636]	["Zhou W", "Ma L", "Yang J", "Qiao H", "	Cell death & disease	2019
Clinical factors associated with worse quality-of-life scores in United States t [PMID:30898373]	["Goswami S", "Peipert B", "Mongelli M",	Surgery	2019
Arabidopsis Duodecuple Mutant of PYL ABA Receptors Reveals PYL Repression of ABA [PMID:29898403]	["Zhao Y", "Zhang Z", "Gao J", "Wang P",	Cell reports	2018
Cell transplantation therapy for spinal cord injury. [PMID:28440805]	["Assinck P", "Duncan G", "Hilton B", "P	Nature neuroscience	2017
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. [PMID:22343897]	["Ichimura A", "Hirasawa A", "Poulain-Go	Nature	2012

Debates (20)

Multi-agent debates referencing this entity

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.00 · 2026-04-27

What is the evidence that blood-brain barrier (BBB) permeability changes serve a

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

closed · Rounds: 7 · Score: 0.50 · 2026-04-26

Can ferroptosis inhibitors prevent BBB disruption and edema formation after card

closed · Rounds: 4 · Score: 0.73 · 2026-04-25

Should PEA-PPARA endocannabinoid signaling be prioritized as a therapeutic strat

closed · Rounds: 4 · Score: 0.76 · 2026-04-23

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

closed · Rounds: 4 · Score: 0.81 · 2026-04-23

The debate highlighted IGFBPL1's potential as a microglial master regulator but

closed · Rounds: 4 · Score: 0.69 · 2026-04-22

Related Research

Hypotheses and analyses mentioning BBB in their description or question text

BBB

Understanding Entity Pages

Summary

Wiki Pages (8)

neurovascular-dysfunction

BBB-Transcytosis Shuttle for Episodic CNS PROTAC Delivery

BBB Transcytosis Shuttle for Episodic CNS PROTAC Delivery

Focused Ultrasound BBB Opening

Brain Shuttle Technologies: BBB Delivery Platforms

AD BBB Modulation and Transport Technologies

Liver-Brain Axis - Hepatic Enzyme-Mediated BBB Protection

BBB-Penetrant Antibody Engineering

Pathway Diagram

Outgoing (112)

Incoming (34)

Targeting Hypotheses (30)

Mentioning Analyses (13)

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Can ferroptosis inhibitors prevent BBB disruption and edema formation after card

Blood-brain barrier tight junction disruption by neuroinflammatory cytokines

How do synthetic EVs achieve brain-specific targeting while avoiding reticuloend

How does engineered C. butyricum cross the blood-brain barrier to directly bind

What determines blood-brain barrier penetration kinetics for specialized pro-res

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

What is the actual quantitative contribution of FcRn-mediated transcytosis to BB

What is the optimal BBB opening duration and spatial precision to maximize thera

What delivery mechanisms can achieve therapeutically relevant CRISPR concentrati

Can IGFBPL1 therapeutics effectively cross the blood-brain barrier to reach CNS

Senescent cell clearance as neurodegeneration therapy

Blood-brain barrier transport mechanisms for antibody therapeutics

Experiments (8)

Related Papers (11)

Debates (20)

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

What is the evidence that blood-brain barrier (BBB) permeability changes serve a

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Can ferroptosis inhibitors prevent BBB disruption and edema formation after card

Should PEA-PPARA endocannabinoid signaling be prioritized as a therapeutic strat

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

The debate highlighted IGFBPL1's potential as a microglial master regulator but

Related Research

APOE4-driven pericyte injury/senescence is an upstream driver of early BBB break

Gut-BBB Axis: Tributyrin/Butyrate HDAC Inhibition Epigenetically Restores Claudi

Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellular BBB Breakdown fr

Endothelial NRF2 Activation as a Master Switch for Post-CA BBB Protection

Soluble LRP1 (sLRP1) Ectodomain Shedding as a Blood-Based Indicator of Impaired

CSF/Serum NfL Ratio Discriminates Active Transcytosis from Passive BBB Breakdown

GFAP-Bearing Circulating Extracellular Vesicles Originating from Reactive Astroc

BBB Integrity Loss Defines Absolute Therapeutic Window Closure

Time-Dependent BBB Repair Strategy

S100B as Active Pathogenic BBB-Disrupting Signal via RAGE/NF-κB/Claudin-5 Axis

Endothelial miR-181c-5p Upregulation Drives Claudin-5 Repression and Paracellula

Circulating Endothelial Microvesicles Expressing Degraded Claudin-5 as Specific

Matrix Metalloproteinase-9 and TIMP-1 Ratio in Peripheral Blood as an Early Indi

Pericyte senescence is sufficient to weaken the BBB even without classic amyloid

Integrated Blood Panel of sPDGFRβ, sTM, and Circulating microRNA-320 Predicts Pr